SCHEDULE: OrbiMed's Compass Therapeutics Stake Dips to 8.9%
Beneficial Ownership Update
OrbiMed Advisors and OrbiMed Capital GP V LLC reported a decrease in their beneficial ownership of Compass Therapeutics, Inc. common stock to 8.9% due to an increase in the number of outstanding shares.
Summary
- OrbiMed Advisors LLC and OrbiMed Capital GP V LLC filed Amendment No. 6 to their Schedule 13D for Compass Therapeutics, Inc.
- The filing reports a decrease in their beneficial ownership of Compass Therapeutics common stock by more than 1%.
- Their aggregate beneficial ownership now stands at 15,219,994 shares, representing approximately 8.9% of the outstanding common stock.
- This decrease in percentage is attributed to an increase in the total number of outstanding shares of Compass Therapeutics, Inc.
- The updated outstanding share count used for calculation is 171,572,498 shares, as disclosed in the Issuer's Rule 424(b)(5) Prospectus filed on August 13, 2025.
Sentiment
Score: 5
Explanation: The filing is largely neutral. The decrease in percentage ownership is due to dilution from an increase in outstanding shares, not a divestment by the reporting persons. OrbiMed maintains a significant stake and board representation, indicating continued interest.
Positives
- The reporting persons continue to hold a significant stake (8.9%), indicating continued investment interest.
- Carl L. Gordon, a member of OrbiMed Advisors, remains on the Board of Directors, providing OrbiMed with influence.
Negatives
- The decrease in percentage ownership, while due to dilution, means OrbiMed's relative influence has slightly diminished.
Risks
- Reporting Persons may acquire or dispose of shares in the future based on various factors, which could impact share price volatility.
- The increase in outstanding shares (dilution) can negatively impact existing shareholder value if not offset by growth.
Future Outlook
The Reporting Persons intend to continuously review their investment in Compass Therapeutics, Inc. based on various factors including the Issuer's business, financial condition, and market conditions. They may acquire additional shares or dispose of existing shares in the open market or privately negotiated transactions depending on their assessment.
Management Comments
- Carl L. Gordon, a member of OrbiMed Advisors, is obligated to transfer any securities issued under stock options or other equity-based compensation received as a non-employee director of Compass Therapeutics, Inc. to OrbiMed Advisors and OrbiMed GP, which will then provide them to OPI V-KA.
Industry Context
This filing reflects a routine update from a significant institutional investor in the biotechnology sector. While the percentage ownership decreased due to share dilution, it does not inherently signal a change in the investor's long-term view of the biotechnology industry or Compass Therapeutics' specific position within it, which often involves capital raises for R&D.
Comparison to Industry Standards
- Not applicable, as this filing primarily concerns a change in beneficial ownership percentage due to share dilution rather than operational or financial results that can be benchmarked against industry peers.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Shareholder Agreement | Carl L. Gordon, a director, is obligated to transfer any equity-based compensation received from the Issuer to OrbiMed Advisors and OrbiMed GP, which will then provide such benefits to OPI V-KA. | NA | Ensures that equity compensation received by the director aligns with the interests of the OrbiMed funds, reinforcing their control over the investment. |
| Shareholder Rights | OPI V-KA and certain other stockholders are party to registration rights agreements with the Issuer, allowing them to require the Issuer to register their shares for resale. | NA | Provides liquidity options for OrbiMed's investment in Compass Therapeutics, facilitating potential future share dispositions. |
Related Party Transactions
- Carl L. Gordon, a member of OrbiMed Advisors and a director of Compass Therapeutics, Inc., is obligated to transfer any equity-based compensation received from the Issuer to OrbiMed Advisors and OrbiMed GP, which will then ensure such benefits are provided to OPI V-KA.
Stakeholder Impact
- Shareholders: The increase in outstanding shares (dilution) could dilute the value of existing shares if not accompanied by proportional growth in company value. The continued significant stake by OrbiMed may be seen as a vote of confidence.
- Management/Board: OrbiMed, through Carl L. Gordon's board seat, retains influence over the Issuer's strategic direction.
Next Steps
- Reporting Persons will continue to review their investment in Compass Therapeutics, Inc.
- Reporting Persons may acquire additional shares or dispose of existing shares in the future based on market conditions and their investment assessment.
Key Dates
| Date | Description |
|---|---|
| 2020-06-19 | Date of Registration Rights Agreement (Exhibit 2). |
| 2020-06-23 | Date of Issuer's Form 8-K filing referencing Registration Rights Agreement (Exhibit 2). |
| 2020-06-29 | Original Schedule 13D filing date. |
| 2021-07-14 | Amendment No. 1 to Schedule 13D filing date. |
| 2021-11-09 | Amendment No. 2 to Schedule 13D filing date and Issuer's Form 10-Q filing referencing Registration Rights Agreement (Exhibit 3). |
| 2022-11-02 | Date of Registration Rights Agreement (Exhibit 3). |
| 2022-11-10 | Amendment No. 3 to Schedule 13D filing date. |
| 2024-03-22 | Amendment No. 4 to Schedule 13D filing date. |
| 2025-04-11 | Amendment No. 5 to Schedule 13D filing date. |
| 2025-08-13 | Date of event requiring filing of this statement; Issuer's Rule 424(b)(5) Prospectus filed with the SEC. |
| 2025-08-15 | Execution date of Joint Filing Agreement and signing date of Amendment No. 6. |
Recommendation
holdThe filing is a routine update on beneficial ownership percentage, primarily reflecting dilution from a capital raise rather than a change in investment thesis by OrbiMed. OrbiMed maintains a substantial stake and board representation, suggesting continued confidence. Without further operational or financial updates from Compass Therapeutics, a 'hold' recommendation is appropriate as the core investment rationale remains unchanged based solely on this filing.
Keywords
Compass Therapeutics, OrbiMed Advisors, OrbiMed Capital, Schedule 13D, beneficial ownership, common stock, biotechnology, pharmaceutical, investment, SEC filing, share dilution
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.